U2Bio Co., Ltd. (KOSDAQ:221800)
South Korea
· Delayed Price · Currency is KRW 19,490
-910 (-4.46%)
At close: Apr 28, 2026
U2Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2014 | 2013 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '14 Dec 31, 2014 | 2013 |
| Operating Revenue | 25,593 | 25,040 | 30,792 | 69,013 | 11,002 | Upgrade
|
| Other Revenue | -0 | - | - | -0 | - | Upgrade
|
| Revenue | 25,593 | 25,040 | 30,792 | 69,013 | 11,002 | Upgrade
|
| Revenue Growth (YoY) | 2.21% | -18.68% | -55.38% | 527.29% | 16.90% | Upgrade
|
| Cost of Revenue | 20,199 | 20,001 | 22,573 | 42,374 | 8,135 | Upgrade
|
| Gross Profit | 5,394 | 5,039 | 8,219 | 26,639 | 2,867 | Upgrade
|
| Selling, General & Admin | 5,230 | 5,644 | 7,432 | 8,351 | 1,921 | Upgrade
|
| Research & Development | 2,104 | 2,110 | 1,685 | 2,129 | 157.15 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | - | 5.99 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 0.57 | Upgrade
|
| Operating Expenses | 7,586 | 7,967 | 9,557 | 10,931 | 2,181 | Upgrade
|
| Operating Income | -2,192 | -2,928 | -1,338 | 15,708 | 685.8 | Upgrade
|
| Interest Expense | -37.23 | -42.62 | -36.32 | -86.25 | -374.37 | Upgrade
|
| Interest & Investment Income | 1,047 | 1,287 | 1,355 | 555.15 | 9.96 | Upgrade
|
| Currency Exchange Gain (Loss) | -17.16 | 50.03 | 5.55 | 26.78 | 10.48 | Upgrade
|
| Other Non Operating Income (Expenses) | -86.54 | -0.66 | 96.98 | -43.48 | -60.19 | Upgrade
|
| EBT Excluding Unusual Items | -1,286 | -1,634 | 83.63 | 16,160 | 271.68 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 6.21 | -71.54 | - | Upgrade
|
| Asset Writedown | -36.91 | 13.64 | -51.69 | -22.7 | - | Upgrade
|
| Pretax Income | -1,323 | -1,620 | 38.15 | 16,066 | 271.68 | Upgrade
|
| Income Tax Expense | 318.89 | 1,220 | -607.74 | 2,906 | - | Upgrade
|
| Net Income | -1,642 | -2,840 | 645.9 | 13,160 | 271.68 | Upgrade
|
| Net Income to Common | -1,642 | -2,840 | 645.9 | 13,160 | 271.68 | Upgrade
|
| Net Income Growth | - | - | -95.09% | 4743.99% | 98.66% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 11 | 10 | 10 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 11 | 10 | 10 | 1 | Upgrade
|
| Shares Change (YoY) | 3.32% | 9.26% | 2.14% | 598.90% | 22.57% | Upgrade
|
| EPS (Basic) | -141.00 | -252.00 | 62.61 | 1303.00 | 188.00 | Upgrade
|
| EPS (Diluted) | -141.00 | -252.00 | 62.61 | 1303.00 | 188.00 | Upgrade
|
| EPS Growth | - | - | -95.19% | 593.09% | 62.07% | Upgrade
|
| Free Cash Flow | -1,654 | -1,775 | -2,769 | 23,439 | -1,482 | Upgrade
|
| Free Cash Flow Per Share | -142.02 | -157.44 | -268.41 | 2320.73 | -1025.56 | Upgrade
|
| Gross Margin | 21.08% | 20.13% | 26.69% | 38.60% | 26.05% | Upgrade
|
| Operating Margin | -8.56% | -11.69% | -4.35% | 22.76% | 6.23% | Upgrade
|
| Profit Margin | -6.42% | -11.34% | 2.10% | 19.07% | 2.47% | Upgrade
|
| Free Cash Flow Margin | -6.46% | -7.09% | -8.99% | 33.96% | -13.47% | Upgrade
|
| EBITDA | -1,357 | -2,050 | -419.13 | 16,596 | 917.55 | Upgrade
|
| EBITDA Margin | -5.30% | -8.19% | -1.36% | 24.05% | 8.34% | Upgrade
|
| D&A For EBITDA | 834.91 | 877.21 | 918.87 | 887.97 | 231.75 | Upgrade
|
| EBIT | -2,192 | -2,928 | -1,338 | 15,708 | 685.8 | Upgrade
|
| EBIT Margin | -8.56% | -11.69% | -4.35% | 22.76% | 6.23% | Upgrade
|
| Effective Tax Rate | - | - | - | 18.09% | - | Upgrade
|
| Advertising Expenses | - | - | - | - | 1.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.